| Issuer | % of Class | Filed | |||
|---|---|---|---|---|---|
|
NewAmsterdam Pharma Company N.V
13D/A
Amendment 7
NAMS · N62509109
|
8.7% |
9/22/2026
Event 9/18/2026
|
|||
| Frazier Life Sciences X, L.P. | 6.1% | ||||
| Frazier Lifesciences Sponsor LLC | 3.3% | ||||
| FHMLS X, L.P. | 6.1% | ||||
| FHMLS X, L.L.C. | 6.1% | ||||
| Frazier Life Sciences Public Fund, L.P. | 8.7% | ||||
| FHMLSP, L.P. | 8.7% | ||||
| FHMLSP, L.L.C. | 8.7% | ||||
| Frazier Life Sciences XI, L.P. | 1.1% | ||||
| FHMLS XI, L.P. | 1.1% | ||||
| FHMLS XI, L.L.C. | 1.1% | ||||
| Frazier Life Sciences XII, L.P. | 0.3% | ||||
| FHMLS XII, L.P. | 0.3% | ||||
| FHMLS XII, L.L.C. | 0.3% | ||||
| James N. Topper | 6.1% | ||||
| Patrick J. Heron | 6.1% | ||||
|
NewAmsterdam Pharma Company N.V
13D/A
Amendment 6
NAMS · N62509109
|
7.7% |
11/4/2025
Event 11/1/2025
|
|||
| Frazier Life Sciences X, L.P. | 6.5% | ||||
| Frazier Lifesciences Sponsor LLC | 3.5% | ||||
| FHMLS X, L.P. | 6.5% | ||||
| FHMLS X, L.L.C. | 6.5% | ||||
| Frazier Life Sciences Public Fund, L.P. | 7.7% | ||||
| FHMLSP, L.P. | 7.7% | ||||
| FHMLSP, L.L.C. | 7.7% | ||||
| Frazier Life Sciences XI, L.P. | 1.0% | ||||
| FHMLS XI, L.P. | 1.0% | ||||
| FHMLS XI, L.L.C. | 1.0% | ||||
| Frazier Life Sciences XII, L.P. | 0.1% | ||||
| FHMLS XII, L.P. | 0.1% | ||||
| FHMLS XII, L.L.C. | 0.1% | ||||
| James N. Topper | 6.5% | ||||
| Patrick J. Heron | 6.5% | ||||
|
NewAmsterdam Pharma Company N.V
13D/A
Amendment 5
NAMS · N62509109
|
6.5% |
8/20/2025
Event 8/18/2025
|
|||
| Frazier Life Sciences X, L.P. | 6.5% | ||||
| Frazier Lifesciences Sponsor LLC | 3.5% | ||||
| FHMLS X, L.P. | 6.5% | ||||
| FHMLS X, L.L.C. | 6.5% | ||||
| Frazier Life Sciences Public Fund, L.P. | 5.0% | ||||
| FHMLSP, L.P. | 5.0% | ||||
| FHMLSP, L.L.C. | 5.0% | ||||
| Frazier Life Sciences Public Overage Fund, L.P. | 2.6% | ||||
| FHMLSP Overage, L.P. | 2.6% | ||||
| FHMLSP Overage, L.L.C. | 2.6% | ||||
| Frazier Life Sciences XI, L.P. | 1.0% | ||||
| FHMLS XI, L.P. | 1.0% | ||||
| FHMLS XI, L.L.C. | 1.0% | ||||
| Frazier Life Sciences XII, L.P. | 0.1% | ||||
| FHMLS XII, L.P. | 0.1% | ||||
| FHMLS XII, L.L.C. | 0.1% | ||||
| James N. Topper | 6.5% | ||||
| Patrick J. Heron | 6.5% | ||||
| Albert Cha | 0% | ||||
| James Brush | 0% | ||||
| Daniel Estes | 0% | ||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.